ADC Therapeutics’ (ADCT) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of ADC Therapeutics (NYSE:ADCT – Free Report) in a research report report published on Friday,Benzinga reports. A number of other analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of ADC Therapeutics in a research […]
Cantor Fitzgerald reissued their overweight rating on shares of ADC Therapeutics (NYSE:ADCT – Free Report) in a research report report published on Friday,Benzinga reports. A number of other analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of ADC Therapeutics in a research […]
